Table 1. Antiviral Activity of Nontoxic Doses of Synthesized Compounds against Herpes Simplex Virus, CBV4, HAV HM 175, HCVcc Genotype 4 & Adenovirus Type 7.
| mean
% of reduction |
|||||
|---|---|---|---|---|---|
| compd no.c | herpes simplex virus | CBV4 | HAV HM 175 | HCVcc genotype 4 | adenovirus type 7 |
| 3b | 26.7 ± 0.20 | 20.0 ± 0.20 | 40.0 ± 0.30 | 20.0 ± 0.25 | 30.0 ± 0.30 |
| 8a | 30.0 ± 0.25 | a | 20.0 ± 0.10 | ||
| 8b | 33.3 ± 0.25 | 30.0 ± 0.15 | 36.7 ± 0.30 | 26.7 ± 0.25 | 20.0 ± 0.20 |
| 8c | 10.0 ± 0.15 | 13.3 ± 0.10 | 10.0 ± 0.15 | 16.7 ± 0.15 | 10.0 ± 0.15 |
| 8d | |||||
| 9a | 20.0 ± 0.15 | 13.3 ± 0.10 | 10.0 ± 0.10 | 13.3 ± 0.10 | 10.0 ± 0.10 |
| 9b | |||||
| 13a | 20.0 ± 0.30 | 20.0 ± 0.10 | 13.3 ± 0.10 | 20.0 ± 0.15 | 10.0 ± 0.10 |
| 15a | |||||
| 15b | 30.0 ± 0.30 | 40.0 ± 0.20 | 20.0 ± 0.10 | 33.3 ± 0.10 | 13.3 ± 0.50 |
| 15c | 50.0 ± 0.35 | 53.3 ± 0.30 | 50.0 ± 0.30 | 20.0 ± 0.15 | 36.7 ± 0.30 |
| 15d | 50.0 ± 0.30 | 50.0 ± 0.35 | 36.7 ± 0.25 | 20.0 ± 0.20 | 30.0 ± 0.10 |
| acyclovir | 99.6 ± 2.80 | NTb | NT | NT | NT |
a
No activity.
b
NT = not tested.
c
All data were taken as the average of three independent measurements.